These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 20166937)

  • 1. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms.
    Schenone S; Brullo C; Botta M
    Curr Med Chem; 2010; 17(13):1220-45. PubMed ID: 20166937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.
    Lu XY; Cai Q; Ding K
    Curr Med Chem; 2011; 18(14):2146-57. PubMed ID: 21517764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into small-molecule inhibitors of Bcr-Abl.
    Schenone S; Bruno O; Radi M; Botta M
    Med Res Rev; 2011 Jan; 31(1):1-41. PubMed ID: 19714578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
    Liu J; Zhang Y; Huang H; Lei X; Tang G; Cao X; Peng J
    Chem Biol Drug Des; 2021 Mar; 97(3):649-664. PubMed ID: 33034143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone.
    Kimura S
    Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):347-55. PubMed ID: 18221045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
    Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y
    Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The second generation of BCR-ABL tyrosine kinase inhibitors.
    Tauchi T; Ohyashiki K
    Int J Hematol; 2006 May; 83(4):294-300. PubMed ID: 16757427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-Abl tyrosine kinase inhibitors: a patent review.
    Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
    Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
    Melge AR; Kumar LG; K P; Nair SV; K M; C GM
    J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.